This is clinically relevant, as ADRB2 and TRK1 can be blocked with β-blockers, drugs used for the treatment of hypertension, and entrectinib, an inhibitor of TRK1 that is currently used for malignancies carrying NTRK gene fusions [23]. The gene discussed is NTRK1; the disease is hypertensive disorder.